New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
08:48 EDTISISIsis CEO says APOC3 data 'really exciting,' NY Times reports
Following the publication of new studies that independently identified mutations in the APOC3 gene that protect against heart attacks, the CEO of Isis Pharmaceuticals, Stanley Crooke, whose company is developing a drug that counteracts the gene, said, "Trust me, these data are really exciting" and called the product "the most important drug" in the company's pipeline, according to The New York Times. Experts see the findings leading to a push to develop drugs that mimic the effect of the mutations, but caution that drug development takes years and that there are no guarantees that new treatments will succeed, the report noted. Shares of Isis are up 4% in pre-market trading following the study publications. Reference Link
News For ISIS From The Last 14 Days
Check below for free stories on ISIS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 22, 2014
12:39 EDTISISThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
August 15, 2014
07:01 EDTISISIsis Pharmaceuticals earns $2M from advancement of ISIS-SMN from Biogen
Isis Pharmaceuticals (ISIS) announced that it has earned a $2M milestone payment from Biogen (BIIB) related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use